Supplemental material
Xenobiotic transporters
Do differences in cell lines and methods used for calculation of IC50 values influence categorisation of drugs as P-glycoprotein substrates and inhibitors?
Donna A. VolpeOffice of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USACorrespondence[email protected]
https://orcid.org/0000-0002-8286-9679View further author information
https://orcid.org/0000-0002-8286-9679View further author information, Abhay JoshiOffice of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, MD, USAhttps://orcid.org/0000-0002-8721-6503View further author information
https://orcid.org/0000-0002-8721-6503View further author information &